| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TSTD3 |
| Uniprot No | H0UI37 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMKIEKCG WSEGLTSIKG NCHNFYTAIS KDVTYKELKN LLNSKNIMLI DVREIWEILE YQKIPESINV PLDEVGEALQ MNPRDFKEKY NEVKPSKSDS |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TSTD3(硫代硫酸盐硫转移酶/硫代谢相关蛋白)重组蛋白研究的参考文献示例。由于TSTD3研究相对较少，部分文献可能涉及相关功能或技术方法，以下为根据领域知识整理的示例：
---
1. **文献名称**：*Recombinant expression and biochemical characterization of human TSTD3: insights into its role in sulfur metabolism*
**作者**：Smith J, et al.
**摘要**：本研究在大肠杆菌中成功表达并纯化了重组人源TSTD3蛋白，通过酶动力学实验证实其具有硫代硫酸盐转移酶活性，并揭示了其在细胞硫代谢通路中可能的调控作用。
2. **文献名称**：*Structural analysis of TSTD3 reveals a conserved rhodanese-like domain critical for substrate binding*
**作者**：Li X, et al.
**摘要**：作者通过X射线晶体学解析了重组TSTD3蛋白的三维结构，发现其具有典型的硫转移酶结构域，并鉴定出关键活性位点残基，为理解其催化机制提供了结构基础。
3. **文献名称**：*TSTD3 recombinant protein mitigates oxidative stress in cellular models via persulfide production*
**作者**：Wang Y, et al.
**摘要**：研究利用哺乳动物细胞表达系统制备重组TSTD3.证明其通过催化硫传递反应生成硫化代谢物，显著降低细胞内氧化应激水平，提示其潜在抗氧化治疗价值。
4. **文献名称**：*Development of a high-throughput assay for screening TSTD3 inhibitors using recombinant protein*
**作者**：Garcia R, et al.
**摘要**：该文献报道了一种基于重组TSTD3蛋白的高通量酶活性检测方法，用于筛选小分子抑制剂，为靶向TSTD3的药物开发提供了技术平台。
---
**备注**：以上文献为示例性质，实际研究中建议通过PubMed、Web of Science等数据库以“TSTD3 recombinant”“thiosulfate sulfurtransferase expression”等关键词检索最新文献。若聚焦特定物种(如人、小鼠)或疾病模型，可进一步细化检索策略。
TSTD3 (Thiosulfate Sulfurtransferase-like Domain Containing 3), also known as TSTD3 or 3-mercaptopyruvate sulfurtransferase (3-MST), is a mitochondrial enzyme critical in cellular sulfur metabolism. It catalyzes the conversion of 3-mercaptopyruvate to pyruvate, releasing hydrogen sulfide (H₂S), a gaseous signaling molecule involved in vasodilation, anti-inflammatory responses, and redox regulation. TSTD3 is part of the sulfurtransferase family and operates in tandem with cysteine aminotransferase (CAT) to form the CAT/3-MST pathway, a key endogenous H₂S production route distinct from the cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) systems.
Recombinant TSTD3 protein is engineered using molecular cloning techniques, often expressed in bacterial or mammalian systems to ensure proper post-translational modifications. Its production enables detailed biochemical studies, including enzymatic activity assays, structural analysis (e.g., crystallography), and interaction studies with substrates or inhibitors. Researchers utilize recombinant TSTD3 to explore its role in diseases linked to H₂S dysregulation, such as cardiovascular disorders, neurodegenerative conditions, and cancer, where altered H₂S levels influence tumor growth and metastasis.
Recent studies highlight TSTD3's therapeutic potential. Inhibitors targeting TSTD3 are investigated for cancer treatment, while enhancing its activity may benefit conditions like hypertension or ischemia-reperfusion injury. The recombinant protein also aids in developing diagnostic tools and screening platforms for drug discovery. Despite progress, challenges remain in understanding tissue-specific H₂S regulation and optimizing TSTD3-based therapies, driving ongoing research into its molecular mechanisms and physiological impacts.
×
